A Randomized Double-blinded Controlled Clinical Trial of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2
Latest Information Update: 09 Dec 2022
At a glance
- Drugs Camostat mesilate (Primary)
- Indications COVID 2019 infections
- Focus Registrational; Therapeutic Use
- Sponsors Daewoong Pharmaceutical
- 04 Dec 2022 Status changed from not yet recruiting to discontinued.
- 27 Jan 2021 New trial record